Innate Pharma (IPHA) Profit After Tax (2018 - 2025)
Historic Profit After Tax for Innate Pharma (IPHA) over the last 8 years, with Q2 2025 value amounting to -$24.2 million.
- Innate Pharma's Profit After Tax fell 14529.87% to -$24.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$31.8 million, marking a year-over-year decrease of 17053.5%. This contributed to the annual value of -$53.5 million for FY2024, which is 55388.88% down from last year.
- Latest data reveals that Innate Pharma reported Profit After Tax of -$24.2 million as of Q2 2025, which was down 14529.87% from -$52.9 million recorded in Q4 2024.
- In the past 5 years, Innate Pharma's Profit After Tax ranged from a high of $57.1 million in Q2 2021 and a low of -$60.4 million during Q4 2021
- For the 5-year period, Innate Pharma's Profit After Tax averaged around -$5.0 million, with its median value being -$8.1 million (2023).
- Its Profit After Tax has fluctuated over the past 5 years, first surged by 9990.19% in 2022, then plummeted by 1363978.38% in 2023.
- Quarter analysis of 5 years shows Innate Pharma's Profit After Tax stood at -$60.4 million in 2021, then surged by 99.9% to -$59279.4 in 2022, then crashed by 13639.78% to -$8.1 million in 2023, then tumbled by 549.05% to -$52.9 million in 2024, then surged by 54.3% to -$24.2 million in 2025.
- Its Profit After Tax was -$24.2 million in Q2 2025, compared to -$52.9 million in Q4 2024 and $53.3 million in Q2 2024.